MA50817A - Formes et formulations solides de (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide - Google Patents

Formes et formulations solides de (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide

Info

Publication number
MA50817A
MA50817A MA050817A MA50817A MA50817A MA 50817 A MA50817 A MA 50817A MA 050817 A MA050817 A MA 050817A MA 50817 A MA50817 A MA 50817A MA 50817 A MA50817 A MA 50817A
Authority
MA
Morocco
Prior art keywords
ynoyl
pyrazin
imidazo
pyrrolidin
benzamide
Prior art date
Application number
MA050817A
Other languages
English (en)
Other versions
MA50817B1 (fr
Inventor
Edwin Aret
Tjeerd Barf
Fritz Blatter
Jerry Evarts
Tim Ingallinera
Cecile Krejsa
Original Assignee
Acerta Pharma Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56363881&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA50817(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Acerta Pharma Bv filed Critical Acerta Pharma Bv
Publication of MA50817A publication Critical patent/MA50817A/fr
Publication of MA50817B1 publication Critical patent/MA50817B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
MA50817A 2015-07-02 2016-07-01 Formes et formulations solides de (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide MA50817B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562188468P 2015-07-02 2015-07-02
US201562271708P 2015-12-28 2015-12-28

Publications (2)

Publication Number Publication Date
MA50817A true MA50817A (fr) 2021-04-21
MA50817B1 MA50817B1 (fr) 2021-10-29

Family

ID=56363881

Family Applications (1)

Application Number Title Priority Date Filing Date
MA50817A MA50817B1 (fr) 2015-07-02 2016-07-01 Formes et formulations solides de (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide

Country Status (29)

Country Link
US (7) US9796721B2 (fr)
EP (4) EP3613745B1 (fr)
JP (3) JP6829215B2 (fr)
KR (2) KR102688052B1 (fr)
CN (2) CN108349978B (fr)
AU (3) AU2016286548B2 (fr)
CA (1) CA2991096A1 (fr)
CL (1) CL2017003445A1 (fr)
CY (3) CY1124519T1 (fr)
DK (3) DK3613745T3 (fr)
ES (3) ES2946489T3 (fr)
FI (1) FI3954690T3 (fr)
HK (1) HK1250511A1 (fr)
HR (3) HRP20211511T1 (fr)
HU (3) HUE056008T2 (fr)
IL (3) IL293821A (fr)
LT (3) LT3954690T (fr)
MA (1) MA50817B1 (fr)
MD (1) MD3317281T2 (fr)
MX (2) MX2020014163A (fr)
MY (1) MY193514A (fr)
PL (3) PL3317281T3 (fr)
PT (3) PT3317281T (fr)
RS (3) RS60411B1 (fr)
RU (1) RU2018103913A (fr)
SG (1) SG10201913796UA (fr)
SI (3) SI3613745T1 (fr)
WO (1) WO2017002095A1 (fr)
ZA (2) ZA201800329B (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3179991B1 (fr) * 2014-08-11 2021-10-06 Acerta Pharma B.V. Combinaisons thérapeutiques d'un inhibiteur de btk et d'un inhibiteur de bcl-2
ES2946489T3 (es) 2015-07-02 2023-07-19 Acerta Pharma Bv Formas sólidas y formulaciones de (S)-4-(8-amino-3-(1-(but-2-inoil)pirrolidin-2-il)imidazo[1,5-a]pirazin-1-il)-N-(piridin-2-il)benzamida
WO2018064797A1 (fr) 2016-10-05 2018-04-12 杭州领业医药科技有限公司 Forme cristalline d'acp-196, procédé de préparation et composition pharmaceutique associés
WO2018115965A1 (fr) * 2016-12-23 2018-06-28 Acerta Pharma Bv Formes solides de composés d'imidazopyrazine
CN110312723B (zh) * 2017-02-20 2022-02-11 杭州领业医药科技有限公司 Acp-196盐的晶型、其制备方法、药物组合物和用途
KR20190130625A (ko) * 2017-03-27 2019-11-22 테사로, 인코포레이티드 니라파립 제제
SG11201909011PA (en) 2017-03-27 2019-10-30 Tesaro Inc Niraparib compositions
WO2018229613A1 (fr) * 2017-06-13 2018-12-20 Dr. Reddy's Laboratories Limited Formes solides d'acalabrutinib et procédé de préparation correspondant
WO2019041026A1 (fr) * 2017-08-29 2019-03-07 Apotex Inc. Nouvelles formes cristallines d'acalabrutinib
EA202090573A1 (ru) 2017-09-26 2020-09-07 Тесаро, Инк. Составы нирапариба
WO2019105359A1 (fr) * 2017-11-30 2019-06-06 苏州科睿思制药有限公司 Forme cristalline de l'acalabrutinib, son procédé de préparation et son application
WO2019134455A1 (fr) 2018-01-05 2019-07-11 苏州科睿思制药有限公司 Nouvelle forme cristalline d'acalabrutinib, son procédé de préparation et son utilisation
WO2019159097A1 (fr) * 2018-02-14 2019-08-22 Sun Pharmaceutical Industries Limited Nouvelles formes polymorphes cristallines d'acalabrutinib
WO2019205812A1 (fr) * 2018-04-26 2019-10-31 苏州科睿思制药有限公司 Nouvelle forme cristalline de l'acalabrutinib, son procédé de préparation et son utilisation
EP3587421A1 (fr) 2018-06-29 2020-01-01 Sandoz AG Formes cristallines de (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo [1,5-alpha]pyrazin-1-yl-n-(pyridin-2-yl)benzamide
IL312413A (en) 2018-08-29 2024-06-01 Acerta Pharma Bv Processes for the preparation of 4-{8-amino-3-[(2S)-1-(but-2-inol)-pyrrolidine-2-YL]imidazo[1,5-A]-pyrazine-1-YL}N- (pyridine-2-YL)-benzamide
WO2020053795A2 (fr) 2018-09-13 2020-03-19 Fresenius Kabi Oncology Ltd. Procédé de préparation d'acalabrutinib et de ses intermédiaires
WO2020065667A1 (fr) 2018-09-25 2020-04-02 Cipla Limited Nouveaux polymorphes d'acalabrutinib, un inhibiteur de la tyrosine kinase de bruton
US20220153744A1 (en) 2019-03-27 2022-05-19 Assia Chemical Industries Ltd. Solid state forms of acalabrutinib
WO2020225831A1 (fr) * 2019-05-09 2020-11-12 Msn Laboratories Private Limited, R&D Center Procédé amélioré pour la préparation de 4-{8-amino-3-[(2s)-1-(but-2-ynoyl)pyrrolidin-2-yl] imidazo[1,5-a]pyrazin-1-yl)}-n-(pyridine-2-yl)benzamide
WO2021135346A1 (fr) * 2019-12-31 2021-07-08 苏州科睿思制药有限公司 Nouvelle forme cristalline de l'acalabrutinib, son procédé de préparation et son utilisation
WO2021239893A1 (fr) 2020-05-29 2021-12-02 Bend Research, Inc. Dispersion solide amorphe d'acalabrutinib
US20230226049A1 (en) * 2020-06-19 2023-07-20 Acerta Pharma B.V. Acalabrutinib maleate dosage forms
CN112028896A (zh) * 2020-10-14 2020-12-04 奥锐特药业(天津)有限公司 阿卡替尼的新晶型及其制备方法
WO2022153330A1 (fr) * 2021-01-13 2022-07-21 Natco Pharma Limited Compositions pharmaceutiques comprenant de l'acalabrutinib
WO2023014817A1 (fr) 2021-08-03 2023-02-09 Syros Pharmaceuticals, Inc. Compositions et méthodes pour traiter des lymphomes avec un inhibiteur de cdk7 en combinaison avec un inhibiteur de btk
WO2023205279A1 (fr) * 2022-04-19 2023-10-26 The Johns Hopkins University Spectroscopie raman améliorée avec addition de composés aromatiques
WO2024164066A1 (fr) * 2023-02-09 2024-08-15 Apotex Inc Formes cristallines de maléate d'acalabrutinib

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001081031A (ja) 1999-08-30 2001-03-27 Schering Ag 溶解性および経口吸収性を改善したベンズアミド誘導体含有製剤
ATE380814T1 (de) 1999-09-17 2007-12-15 Abbott Gmbh & Co Kg Kinaseinhibitoren als arzneimittel
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
US6998391B2 (en) 2002-02-07 2006-02-14 Supergen.Inc. Method for treating diseases associated with abnormal kinase activity
CN1898240B (zh) 2003-10-15 2011-08-03 Osi制药公司 咪唑并吡嗪类酪氨酸激酶抑制剂
ATE433979T1 (de) 2004-04-02 2009-07-15 Osi Pharm Inc Mit einem 6,6-bicyclischen ring substituierte heterobicyclische proteinkinaseinhibitoren
ITMI20051231A1 (it) 2005-06-29 2006-12-30 Pharmaproducts Uk Ltd Formulazioni farmaceutiche contenenti colostro e calcio folinato per il trattamento delle affezioni del cavo orale
BRPI0615860B8 (pt) 2005-09-09 2021-05-25 Labopharm Barbados Ltd composição farmacêutica de liberação prolongada monolítica sólida
WO2007061737A2 (fr) 2005-11-17 2007-05-31 Osi Pharmaceuticals, Inc. INHIBITEURS mTOR BICYCLIQUES CONDENSES
PE20070855A1 (es) 2005-12-02 2007-10-14 Bayer Pharmaceuticals Corp Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
AR057960A1 (es) 2005-12-02 2007-12-26 Osi Pharm Inc Inhibidores de proteina quinasa biciclicos
JP5372737B2 (ja) 2006-03-13 2013-12-18 オーエスアイ・フアーマシユーテイカルズ・エル・エル・シー Ｅｇｆｒキナーゼ阻害剤およびｅｇｆｒキナーゼ阻害剤の効果に対し腫瘍細胞を感作する薬剤を用いる併用治療
LT2529621T (lt) 2006-09-22 2017-01-10 Pharmacyclics Llc Brutono tirozinkinazės inhibitoriai
CA2874756C (fr) 2007-03-28 2018-05-29 Pharmacyclics, Inc. Inhibiteurs de la tyrosine kinase de bruton
US20120101114A1 (en) 2007-03-28 2012-04-26 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
US8088824B2 (en) * 2007-08-15 2012-01-03 Reata Pharmaceuticals Inc. Forms of CDDO methyl ester
WO2009076170A2 (fr) 2007-12-13 2009-06-18 Novartis Ag Combinaisons d'agents thérapeutiques pour le traitement du cancer
US9095592B2 (en) 2008-11-07 2015-08-04 The Research Foundation For The State University Of New York Bruton's tyrosine kinase as anti-cancer drug target
US8299077B2 (en) 2009-03-02 2012-10-30 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
US8765754B2 (en) 2009-04-29 2014-07-01 Locus Pharmaceuticals, Inc. Pyrrolotriazine compounds
CA2787291C (fr) 2010-02-08 2016-04-19 Msd Oss B.V. Composes de 8-methyl-1-phenyl-imidazol[1,5-a]pyrazine
CN102190594A (zh) * 2010-03-17 2011-09-21 上海医药工业研究院 阿戈美拉汀氯化氢水合物及其制备方法
UY33288A (es) 2010-03-25 2011-10-31 Glaxosmithkline Llc Derivados de indolina inhibidores de la proteina quinasa r del reticulo endoplasmatico
JP5648686B2 (ja) 2010-05-31 2015-01-07 小野薬品工業株式会社 プリノン誘導体
EA031737B1 (ru) 2010-06-03 2019-02-28 Фармасайкликс, Инк. Применение ингибиторов тирозинкиназы брутона (btk) для лечения лейкоза и лимфомы
US20120053189A1 (en) 2010-06-28 2012-03-01 Pharmacyclics, Inc. Btk inhibitors for the treatment of immune mediated conditions
CA2836449C (fr) 2011-05-17 2021-04-27 The Regents Of The University Of California Inhibiteurs de kinase
BR112013033534A2 (pt) 2011-06-28 2017-02-07 Pharmacyclics Inc métodos e composições para inibição de reabsorção de osso
AU2012283775A1 (en) 2011-07-13 2014-01-23 Pharmacyclics Llc Inhibitors of Bruton's tyrosine kinase
EP2548877A1 (fr) 2011-07-19 2013-01-23 MSD Oss B.V. Dérivés de 4-(pyridine condensée à 5 chaînons)benzamide comme inhibiteurs de BTK
CA2841887A1 (fr) 2011-07-19 2013-01-24 Merck Sharp & Dohme B.V. 4-imidazopyridazin-1-yl-benzamides et 4-imidazotriazin-1-yl-benzamides inhibiteurs de btk
CA2841886C (fr) * 2011-07-19 2016-08-16 Merck Sharp & Dohme B.V. 4-imidazopyridazin-1-yl-benzamides et 4-imidazotriazin-1-yl-benzamides en tant qu'inhibiteurs de btk
MX361772B (es) 2011-10-19 2018-12-17 Pharmacyclics Llc Uso de inhibidores de la tirosina cinasa de bruton (btk).
US20140212425A1 (en) 2011-12-05 2014-07-31 Immunomedics, Inc. Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
CA2873979C (fr) * 2012-05-23 2019-11-12 Nerviano Medical Sciences S.R.L. Procede de preparation du n-[5-(3,5-difluoro-benzyl)-1h-indazol-3-yl]-4-(4-methyl-piperazine-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide
TW201441234A (zh) 2013-01-23 2014-11-01 Merck Sharp & Dohme Ｂｔｋ抑制劑
EA201591718A1 (ru) 2013-03-14 2016-05-31 Фармасайкликс Элэлси Комбинации ингибиторов тирозинкиназы брутона и ингибиторов cyp3a4
WO2014143807A2 (fr) 2013-03-15 2014-09-18 Stromatt Scott Anticorps anti-cd37 et polythérapie par antagoniste de la voie bcr pour le traitement de malignités b et de troubles des lymphocytes b
WO2014168975A1 (fr) 2013-04-08 2014-10-16 Pharmacyclics, Inc. Combinaison thérapeutique à base d'ibrutinib
CN105263497B (zh) 2013-04-08 2019-04-30 拜耳制药股份公司 取代的2,3-二氢咪唑并[1,2-c]喹唑啉治疗淋巴瘤的用途
WO2015018522A1 (fr) 2013-08-06 2015-02-12 Oncoethix Sa Inhibiteur de bromodomaine bet présentant une synergie avec plusieurs agents anti-cancéreux dans des modèles cliniques de lymphome diffus de cellule b de grande taille (dlbcl)
WO2015057992A1 (fr) * 2013-10-16 2015-04-23 Izumi Raquel Inhibiteurs btk pour la mobilisation hématopoïétique
EP3076974A1 (fr) 2013-12-05 2016-10-12 Acerta Pharma B.V. Association thérapeutique d'un inhibiteur de pi3k et d'un inhibiteur de btk
JP6219523B2 (ja) 2013-12-13 2017-10-25 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ブルトンチロシンキナーゼの阻害剤
WO2015110923A2 (fr) 2014-01-21 2015-07-30 Acerta Pharma B.V. Méthodes de traitement de la leucémie lymphoïde chronique et du lymphome à petits lymphocytes en utilisant un inhibiteur de btk
FR3021783B1 (fr) 2014-06-02 2016-05-13 Morpho Procede de validation de l'authenticite d'un element du corps humain
ES2946489T3 (es) 2015-07-02 2023-07-19 Acerta Pharma Bv Formas sólidas y formulaciones de (S)-4-(8-amino-3-(1-(but-2-inoil)pirrolidin-2-il)imidazo[1,5-a]pirazin-1-il)-N-(piridin-2-il)benzamida

Also Published As

Publication number Publication date
CL2017003445A1 (es) 2018-05-11
PT3954690T (pt) 2023-06-06
RU2018103913A3 (fr) 2019-12-31
US20170029428A1 (en) 2017-02-02
ES2895802T3 (es) 2022-02-22
EP3317281B1 (fr) 2020-04-22
US9796721B2 (en) 2017-10-24
US10167291B2 (en) 2019-01-01
DK3613745T3 (da) 2021-10-18
IL256633B (en) 2020-05-31
ES2797987T3 (es) 2020-12-04
RS60411B1 (sr) 2020-07-31
US20200255437A1 (en) 2020-08-13
AU2016286548A1 (en) 2018-02-01
IL274066A (en) 2020-06-30
JP7091494B2 (ja) 2022-06-27
SI3954690T1 (sl) 2023-07-31
ES2946489T3 (es) 2023-07-19
LT3613745T (lt) 2021-10-11
AU2020277123B2 (en) 2022-09-29
LT3317281T (lt) 2020-07-27
HUE062258T2 (hu) 2023-10-28
IL274066B (en) 2022-07-01
RS64195B1 (sr) 2023-06-30
JP2022120156A (ja) 2022-08-17
SG10201913796UA (en) 2020-03-30
EP4209493A1 (fr) 2023-07-12
CN108349978B (zh) 2021-07-23
HUE056008T2 (hu) 2022-01-28
RU2018103913A (ru) 2019-08-02
MY193514A (en) 2022-10-17
JP2021073235A (ja) 2021-05-13
US20180208596A1 (en) 2018-07-26
SI3317281T1 (sl) 2020-08-31
MX2018000179A (es) 2018-06-27
PT3613745T (pt) 2021-10-14
EP3954690B1 (fr) 2023-04-05
EP3613745A1 (fr) 2020-02-26
LT3954690T (lt) 2023-05-25
PL3613745T3 (pl) 2022-01-31
EP3613745B1 (fr) 2021-09-01
SI3613745T1 (sl) 2021-12-31
US20240199622A1 (en) 2024-06-20
KR20240115937A (ko) 2024-07-26
CA2991096A1 (fr) 2017-01-05
AU2016286548B2 (en) 2020-12-10
AU2022291635A1 (en) 2023-02-02
JP2018522877A (ja) 2018-08-16
HRP20200934T1 (hr) 2020-09-18
US11820777B2 (en) 2023-11-21
JP6829215B2 (ja) 2021-02-10
AU2020277123A1 (en) 2020-12-24
FI3954690T3 (fi) 2023-05-31
HRP20230417T1 (hr) 2023-07-07
MX2020014163A (es) 2022-09-29
US20190337949A1 (en) 2019-11-07
US20220348582A1 (en) 2022-11-03
ZA201800329B (en) 2022-04-28
PL3317281T3 (pl) 2020-11-02
HK1250511A1 (zh) 2018-12-21
IL256633A (en) 2018-02-28
HRP20211511T1 (hr) 2021-12-24
DK3954690T3 (da) 2023-06-06
US10640509B2 (en) 2020-05-05
CN113480542A (zh) 2021-10-08
CY1124815T1 (el) 2022-11-25
EP3954690A1 (fr) 2022-02-16
KR102688052B1 (ko) 2024-07-25
KR20180048593A (ko) 2018-05-10
HUE049989T2 (hu) 2020-11-30
MD3317281T2 (ro) 2020-07-31
PL3954690T3 (pl) 2023-08-14
US20220177476A1 (en) 2022-06-09
AU2022291635B2 (en) 2024-06-27
RS62455B1 (sr) 2021-11-30
WO2017002095A1 (fr) 2017-01-05
CY1126103T1 (el) 2023-11-15
IL293821A (en) 2022-08-01
US11059829B2 (en) 2021-07-13
ZA202000300B (en) 2022-03-30
EP3317281A1 (fr) 2018-05-09
MA50817B1 (fr) 2021-10-29
CY1124519T1 (el) 2022-03-24
PT3317281T (pt) 2020-06-18
CN108349978A (zh) 2018-07-31
DK3317281T3 (da) 2020-06-15

Similar Documents

Publication Publication Date Title
MA50817A (fr) Formes et formulations solides de (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide
IL262003A (en) Liquid formulations of (s)-n-(5-((r)-2-(5,2-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[5,1-a]pyrimidin-3-yl)-3 -Hydroxypyrrolidine-1-carboxamide
DK3800189T3 (da) Fremstilling af (s)-n-(5-((r)-2-(2,5-difluorphenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidin-1-carboxamid
DK3699181T3 (da) Krystallinsk form af (s)-n-(5-((r)-2-(2,5-difluorphenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidin-1-carboxamidhydrogensulfat
WO2015195863A8 (fr) 2-((4s)-6-(4-chlorophényl)-1-méthyl-4h-benzo[c]isoxazolo[4,5-e]azépine-4-yl)acétamide hydraté
MA57556B1 (fr) Formes et formulations solides de (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide